Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

4 terminated/withdrawn out of 24 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

21%

5 trials in Phase 3/4

Results Transparency

67%

12 of 18 completed trials have results

Key Signals

12 with results

Enrollment Performance

Analytics

Phase 1
11(45.8%)
Phase 2
6(25.0%)
Phase 3
4(16.7%)
N/A
2(8.3%)
Phase 4
1(4.2%)
24Total
Phase 1(11)
Phase 2(6)
Phase 3(4)
N/A(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT06216132Phase 1Completed

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

Role: collaborator

NCT05271552Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Role: collaborator

NCT05547503Phase 1Completed

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Role: collaborator

NCT06245213Phase 2Active Not Recruiting

A Study of ANAVEX3-71 in Adults With Schizophrenia

Role: collaborator

NCT05071430Phase 2Completed

Safety and Efficacy of HB-1 for Panic Disorder

Role: collaborator

NCT04158687Phase 2Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

Role: collaborator

NCT05665088Phase 3Terminated

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Role: collaborator

NCT04470050Phase 1Completed

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

Role: collaborator

NCT04251910Phase 1Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Role: collaborator

NCT04276883Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Role: collaborator

NCT05276830Phase 2Terminated

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Role: collaborator

NCT04970342Phase 1Completed

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

Role: collaborator

NCT04268303Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Role: collaborator

NCT04010305Phase 1Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Role: collaborator

NCT03520517Phase 1Completed

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

Role: collaborator

NCT05313386Phase 2Withdrawn

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

Role: collaborator

NCT03353922Phase 1Completed

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

Role: collaborator

NCT03564548Phase 2Unknown

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

Role: collaborator

NCT03012334Phase 1Completed

The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants

Role: collaborator

NCT02775981Phase 1Completed

Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function

Role: collaborator